共 4 条
Pharmacologic preconditioning of random-pattern skin flap in rats using local cyclosporine and FK-506 - Interaction with nitric oxide system
被引:21
作者:
Ghazinezami, Behtash
Rahimpour, Sina
Gholipour, Taha
Ghasemi, Mehdi
Sadeghipour, Hamed
Mehr, Shahram Ejtemaie
Emami-Razavi, Seyed Hassan
Dehpour, Ahmad Reza
机构:
[1] Univ Tehran Med Sci, Imam Khomeini Hosp, Basic Med Sci Res Ctr, Tehran, Iran
[2] Univ Tehran Med Sci, Sch Med, Dept Pharmacol, Tehran, Iran
[3] Univ Tehran Med Sci, Iranian Tissue Bank Res Ctr, Imam Khomeini Hosp, Tehran, Iran
关键词:
random-pattern skin flap;
ischemic;
pharmacologic preconditioning;
cyclosporine;
FK-506;
tacrolimus;
nitric oxide;
D O I:
10.1097/01.sap.0000258982.86308.f0
中图分类号:
R61 [外科手术学];
学科分类号:
摘要:
It has been suggested that immunophilin ligands such as cyclosporine and FK-506 (tacrolimus) affect the survival of ischemic tissues. Our objective was to show an acute effect of local cyclosporin-A (CsA) and FK-506 on isehemic protection in a random-pattern skin-flap model in rats and investigate the effect of nitric oxide (NO) pathways as a modulator of protection of these agents. Ninety male Sprague-Dawley rats were randomly assigned to treatment groups. Bipedicled dorsal flaps (2 x 8 cm) were elevated at midline. Prior to cutting the cranial pedicle to induce permanent ischemia, pharmacologic preconditioning groups received local injection of CsA (0.3, 1, or 3 nmol/flap) or FK-506 (0.01, 0.03, or 0.1 pmol/flap), and the ischemic preconditioning (IPC) group underwent temporary clamping of the cranial pedicle. At the seventh day postoperatively, the survival of the flaps was measured. In other groups, nitric oxide synthase inhibitor N-omega-nitro-L-arginine methyl ester hydrochloride (L-NAME) was administered with effective CsA and FK-506, and ischemic preconditioning. Nitric oxide precursor L-arginine doses were also studied, and a systemic subeffective dose (100 mg/kg) was coadministered with subeffective CsA and FK-506. Significant increase in flap survival was obtained with CsA (1 nmol/flap), FK-506 (0.1 pmol/flap), and IPC. These protections were abolished by systemic administration of L-NAME (10 mg/kg). Coadministration of subeffective doses of CsA (0.3 nmol/flap) and FK-506 (0.03 pmol/flap), with subeffective systemic L-arginine, significantly improved flap survival. Pharmacologic preconditioning with local, single, low doses of CsA or FK-506 is shown to be even more effective than IPC. Administration of the NOS substrate L-arginine potentiates these effects.
引用
收藏
页码:435 / 440
页数:6
相关论文